Literature DB >> 2529016

The binding of (+)-isradipine by guinea-pig intact atria.

S Herzig1, H Lüllmann.   

Abstract

1. The accumulation of [3H]-(+)-isradipine (PN 200-110) was measured in quiescent guinea-pig left atria with normal (K+ 2.7 mM) or lowered (K+ 40 mM) membrane potential. 2. Under control conditions (2.7 mM K+) a high affinity binding of (+)-isradipine could not be detected. If, however, the atria were partially depolarized to about -30 mV by 40 mM K+, high affinity binding became evident displaying a dissociation constant of 4.2 x 10(-11) M and a capacity of 9.7 nmol kg-1 wet wt. 3. The depolarization-induced binding was reversible upon repolarization of the atria although isradipine was still present in the medium. This indicates that the high affinity binding sites disappear as soon as the cell membranes become polarized. 4. Isradipine belongs to the less hydrophobic dihydropyridines, but nevertheless the unsaturable binding led to an accumulation of about 84 fold. At a concentration of 2 x 10(-8) M (+)-isradipine, which reduces the contractile force by 50%, the cellular concentration will rise to more than 10(-6) M.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529016      PMCID: PMC1854627          DOI: 10.1111/j.1476-5381.1989.tb12585.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  11 in total

1.  Evidence for distinct calcium channel agonist and antagonist binding sites in intact cultured embryonic chick ventricular cells.

Authors:  R T Lee; T W Smith; J D Marsh
Journal:  Circ Res       Date:  1987-05       Impact factor: 17.367

2.  Primary structure of the receptor for calcium channel blockers from skeletal muscle.

Authors:  T Tanabe; H Takeshima; A Mikami; V Flockerzi; H Takahashi; K Kangawa; M Kojima; H Matsuo; T Hirose; S Numa
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

3.  Correlation of nitrendipine and Bay k 8644 binding to isolated canine heart sarcolemma with their pharmacological effects on the canine heart.

Authors:  P L Vaghy; I L Grupp; G Grupp; J L Balwierczak; J S Williams; A Schwartz
Journal:  Eur J Pharmacol       Date:  1984-07-13       Impact factor: 4.432

4.  Voltage-dependent nitrendipine binding to cardiac sarcolemmal vesicles.

Authors:  T J Kamp; R J Miller
Journal:  Mol Pharmacol       Date:  1987-08       Impact factor: 4.436

5.  Effect of membrane depolarization on binding of [3H]nitrendipine to rat cardiac myocytes.

Authors:  F J Green; B B Farmer; G L Wiseman; M J Jose; A M Watanabe
Journal:  Circ Res       Date:  1985-04       Impact factor: 17.367

6.  Felodipine, pharmacodynamics and pharmacokinetics in the isolated rabbit heart.

Authors:  J Askholt; F Nielsen-Kudsk
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-07

7.  Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state.

Authors:  B P Bean
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

8.  High and concentration-proportional accumulation of [3H]-nitrendipine by intact cardiac tissue.

Authors:  H Lüllmann; K Mohr
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

9.  Relationship of binding of a calcium channel blocker to inhibition of contraction in intact cultured embryonic chick ventricular cells.

Authors:  J D Marsh; E Loh; D Lachance; W H Barry; T W Smith
Journal:  Circ Res       Date:  1983-10       Impact factor: 17.367

10.  Studies on Ca channels in intact cardiac cells: voltage-dependent effects and cooperative interactions of dihydropyridine enantiomers.

Authors:  S Kokubun; B Prod'hom; C Becker; H Porzig; H Reuter
Journal:  Mol Pharmacol       Date:  1986-12       Impact factor: 4.436

View more
  1 in total

1.  Potentiation of cardiodepressive action among calcium antagonists from different classes: evidence for a mechanism at the single calcium channel level.

Authors:  S Braun; N Frey; S Herzig; C Hilbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.